TW200640457A - Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes - Google Patents
Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetesInfo
- Publication number
- TW200640457A TW200640457A TW095105631A TW95105631A TW200640457A TW 200640457 A TW200640457 A TW 200640457A TW 095105631 A TW095105631 A TW 095105631A TW 95105631 A TW95105631 A TW 95105631A TW 200640457 A TW200640457 A TW 200640457A
- Authority
- TW
- Taiwan
- Prior art keywords
- diabetes
- rimonabant
- prevention
- preparation
- treatment
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003015 rimonabant Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0501861A FR2882261B1 (fr) | 2005-02-21 | 2005-02-21 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
| FR0504942A FR2882264A1 (fr) | 2005-02-21 | 2005-05-12 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
| FR0505228A FR2882265B1 (fr) | 2005-02-21 | 2005-05-23 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200640457A true TW200640457A (en) | 2006-12-01 |
Family
ID=36809538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095105631A TW200640457A (en) | 2005-02-21 | 2006-02-20 | Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP2008530189A (fr) |
| BR (1) | BRPI0608183A2 (fr) |
| CR (1) | CR9293A (fr) |
| EA (1) | EA011618B1 (fr) |
| FR (2) | FR2882264A1 (fr) |
| IL (1) | IL185401A0 (fr) |
| MA (1) | MA29262B1 (fr) |
| MX (1) | MX2007009996A (fr) |
| TN (1) | TNSN07297A1 (fr) |
| TW (1) | TW200640457A (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
-
2005
- 2005-05-12 FR FR0504942A patent/FR2882264A1/fr not_active Withdrawn
- 2005-05-23 FR FR0505228A patent/FR2882265B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-20 TW TW095105631A patent/TW200640457A/zh unknown
- 2006-02-20 EA EA200701781A patent/EA011618B1/ru not_active IP Right Cessation
- 2006-02-20 JP JP2007555669A patent/JP2008530189A/ja not_active Withdrawn
- 2006-02-20 BR BRPI0608183-5A patent/BRPI0608183A2/pt not_active IP Right Cessation
- 2006-02-20 MX MX2007009996A patent/MX2007009996A/es not_active Application Discontinuation
-
2007
- 2007-07-31 TN TNP2007000297A patent/TNSN07297A1/en unknown
- 2007-08-07 CR CR9293A patent/CR9293A/es unknown
- 2007-08-20 IL IL185401A patent/IL185401A0/en unknown
- 2007-08-23 MA MA30158A patent/MA29262B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0608183A2 (pt) | 2009-11-17 |
| EA200701781A1 (ru) | 2007-12-28 |
| MX2007009996A (es) | 2007-10-10 |
| TNSN07297A1 (en) | 2008-12-31 |
| JP2008530189A (ja) | 2008-08-07 |
| FR2882265A1 (fr) | 2006-08-25 |
| IL185401A0 (en) | 2008-08-07 |
| EA011618B1 (ru) | 2009-04-28 |
| CR9293A (es) | 2007-10-01 |
| FR2882264A1 (fr) | 2006-08-25 |
| FR2882265B1 (fr) | 2009-02-13 |
| MA29262B1 (fr) | 2008-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006096434A3 (fr) | Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete | |
| WO2009002867A3 (fr) | Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire | |
| WO2004021968A3 (fr) | Solution destinee a une application ungueale et peri-ungueale | |
| WO2006096439A3 (fr) | Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees | |
| GB2430157A (en) | Personal care products and methods for inhibiting the adherence of flora to skin | |
| UA100111C2 (ru) | Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона | |
| WO2006013441A3 (fr) | Utilisation de bacteries probiotiques dans la preparation de compositions topiques destinees a la protection de la peau | |
| WO2008009379A3 (fr) | Associations de principes actifs présentant des propriétés insecticides et acaricides | |
| WO2004030611A3 (fr) | Inhibiteurs non nucleosidiques de transcriptases inverses | |
| IL184051A (en) | Acetylated GLP-1 compounds, containing and using pharmaceutical preparations | |
| WO2007112014A3 (fr) | Nouvelles combinaisons thérapeutiques pour le traitement de la dépression | |
| MX2007010560A (es) | Roflumilast para el tratamiento de diabetes mellitus. | |
| WO2006119958A3 (fr) | Utilisation de la flibanserine dans le traitement de la douleur chronique | |
| MY148723A (en) | Use of pinolenic acid for the treatment of obesity | |
| IL187575A (en) | Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders | |
| WO2006116221A3 (fr) | Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques | |
| TNSN07203A1 (en) | Pharmaceutical compositions for the treatment of cellulite | |
| WO2006056696A3 (fr) | 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation | |
| WO2006054182A3 (fr) | Phosphoindoles utilisés en tant qu'inhibiteurs du vih | |
| WO2005082413A3 (fr) | Combinaison de ciclesonide et de glycopyrronium | |
| WO2005053394A3 (fr) | Melanges insecticides synergiques | |
| WO2002017952A3 (fr) | Inhibition de la voie de la proteine mapkkk: une strategie therapeutique selective contre les melanomes | |
| MY140538A (en) | Substituted n-acyl-2-aminothiazoles | |
| MXPA05013121A (es) | Derivados de indol con efecto de induccion de apoptosis. | |
| MX2009008873A (es) | Composicion util para el tratamiento de diabetes tipo 2. |